4/18
07:00 am
agio
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Low
Report
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
4/9
08:44 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
4/9
07:15 am
agio
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report [Yahoo! Finance]
Medium
Report
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report [Yahoo! Finance]
4/9
07:00 am
agio
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Medium
Report
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
3/30
09:56 am
agio
We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth [Yahoo! Finance]
Low
Report
We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth [Yahoo! Finance]
3/5
07:00 am
agio
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Medium
Report
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
2/29
04:24 am
agio
Global PRMT5 Targeted Therapy Market & Clinical Trials Insights 2024: Innovation and Potential in Oncology and Beyond [Yahoo! Finance]
Medium
Report
Global PRMT5 Targeted Therapy Market & Clinical Trials Insights 2024: Innovation and Potential in Oncology and Beyond [Yahoo! Finance]
2/28
06:05 pm
agio
Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024: PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase [Yahoo! Finance]
Medium
Report
Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024: PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase [Yahoo! Finance]
2/23
01:09 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at JPMorgan Chase & Co. from $31.00 to $30.00. They now have a "neutral" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at JPMorgan Chase & Co. from $31.00 to $30.00. They now have a "neutral" rating on the stock.
2/22
07:00 am
agio
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
High
Report
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
2/20
08:38 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/18
07:26 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]
2/17
07:23 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]
2/16
12:38 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at Royal Bank of Canada from $43.00 to $42.00. They now have an "outperform" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at Royal Bank of Canada from $43.00 to $42.00. They now have an "outperform" rating on the stock.
2/16
11:13 am
agio
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates [Yahoo! Finance]
Low
Report
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates [Yahoo! Finance]
2/15
08:05 am
agio
Agios Pharmaceuticals Inc (AGIO) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Agios Pharmaceuticals Inc (AGIO) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/15
07:12 am
agio
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
2/15
07:00 am
agio
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Medium
Report
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2/8
07:40 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
2/6
12:13 pm
agio
Sickle Cell Disease Treatment Market Size Projections Exhibit a CAGR of 20%, Likely to Attain a Value of USD 12.38 Billion by 2032 [Yahoo! Finance]
Low
Report
Sickle Cell Disease Treatment Market Size Projections Exhibit a CAGR of 20%, Likely to Attain a Value of USD 12.38 Billion by 2032 [Yahoo! Finance]
2/2
07:00 am
agio
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
Low
Report
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
1/31
05:21 am
agio
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs [Yahoo! Finance]
Low
Report
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs [Yahoo! Finance]